Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors

Table 1

HDACi combination regimens currently in clinical trials. Partial list of clinical trials evaluating the combination of HDACi with other anticancer agents discussed in this paper (source: http://www.clinicaltrials.gov/, http://www.cancer.gov/clincialtrials).

HDACi	Other Intervention	Tumor Type
Entinostat (SNDX-275)	azacitidine	leukemia, MDS, colorectal cancer, NSCLC
Mocetinostat (MGCD0103)	azacitidine	MDS
Panobinostat (LBH589)	azacitidine	MDS, CML, AML
	bortezomib	peripheral T cell lymphoma, NK/T cell lymphoma, MM, pancreatic cancer
	bortezomib, dexamethasone	MM
	decitabine	MDS, AML
	decitabine, temozolomide	melanoma
	radiation therapy	prostate cancer, esophageal cancer, head and neck cancer
PCI-24781	doxorubicin	sarcoma
Romidepsin	bortezomib	myeloma
Valproic acid	azacitidine	advanced cancers
	azacitidine, ATRA	AML, MDS
	decitabine, ATRA	AML
	radiation therapy, bevacizumab	children with high grade gliomas
	radiation therapy, temozolomide	high grade gliomas, brain tumors
Vorinostat	azacitidine	AML, MDS, DLBCL, lymphoma, MM, NSCLC, Non-Hodgkin's lymphoma
	bortezomib, AMG 655	lymphoma
	bortezomib, dexamethasone	MM
	cisplatin, pemetrexed, radiation therapy	NSCLC
	cisplatin, radiation therapy	squamous cell carcinoma
	gemtuzumab ozogamicin, azacitidine	AML
	marizomib (NPI-0052)	NSCLC, pancreatic cancer, melanoma, lymphoma
	paclitaxel, radiation therapy	NSCLC
	radiation therapy	brain metastases, NSCLC, pancreatic cancer, pelvic cancer
	radiation therapy, fluorouracil	pancreatic adenocarcinoma

ATRA: all-trans retinoic acid, MM: multiple myeloma, NSCLC: nonsmall cell lung carcinoma, AML: acute myeloid leukemia, CML: chronic myelogenous leukemia, MDS: myelodysplastic syndrome, and DLBCL: Diffuse large B-cell lymphoma.